• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

ASO Author Reflections: What are the Prognostic Factors for Achieving Long-Term Survival in MPM Patients Treated with CRS+HIPEC? Does the Conditional Survival Analysis Provide Special Information?

作者信息

Liang Xin-Li, Li Yan

机构信息

Department of Surgical Oncology, Beijing Tsinghua Changgung Hospital, Tsinghua University, Beijing, China.

Department of Peritoneal Cancer Surgery, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.

出版信息

Ann Surg Oncol. 2025 Apr;32(4):2936-2937. doi: 10.1245/s10434-024-16681-z. Epub 2024 Dec 7.

DOI:10.1245/s10434-024-16681-z
PMID:39645553
Abstract
摘要

相似文献

1
ASO Author Reflections: What are the Prognostic Factors for Achieving Long-Term Survival in MPM Patients Treated with CRS+HIPEC? Does the Conditional Survival Analysis Provide Special Information?ASO作者反思：接受CRS+HIPEC治疗的MPM患者实现长期生存的预后因素有哪些？条件生存分析是否能提供特殊信息？
Ann Surg Oncol. 2025 Apr;32(4):2936-2937. doi: 10.1245/s10434-024-16681-z. Epub 2024 Dec 7.
2
Prognostic Factors of Long-Term Survival and Conditional Survival Analysis in MPM Patients Treated with CRS+HIPEC: A Retrospective Study of Two Centers.接受CRS+HIPEC治疗的MPM患者长期生存的预后因素及条件生存分析：一项对两个中心的回顾性研究
Ann Surg Oncol. 2025 Apr;32(4):2912-2922. doi: 10.1245/s10434-024-16485-1. Epub 2024 Nov 13.
3
Long-Term Survival in Patients Treated with Cytoreduction and Heated Intraperitoneal Chemotherapy for Peritoneal Mesothelioma at a Single High-Volume Center.单家高容量中心行细胞减灭术联合腹腔热灌注化疗治疗腹膜间皮瘤的长期生存结果。
Ann Surg Oncol. 2023 May;30(5):2666-2675. doi: 10.1245/s10434-022-13061-3. Epub 2023 Feb 8.
4
ASO Author Reflections: Long-Term Survival Is Feasible After Complete CRS/HIPEC for Biphasic Peritoneal Mesothelioma.ASO作者反思：对于双相性腹膜间皮瘤，完整的细胞减灭术/腹腔热灌注化疗后长期生存是可行的。
Ann Surg Oncol. 2018 Dec;25(Suppl 3):770-771. doi: 10.1245/s10434-018-7028-y. Epub 2018 Nov 12.
5
National Practice Patterns in Malignant Peritoneal Mesothelioma: Updates in Management and Survival.恶性腹膜间皮瘤的国家实践模式：治疗和生存的最新进展。
Ann Surg Oncol. 2023 Aug;30(8):5119-5129. doi: 10.1245/s10434-023-13528-x. Epub 2023 May 4.
6
ASO Author Reflections: Evaluating HIPEC Switch for Repeat CRS-HIPEC, Time to End a Common Practice?美国外科肿瘤学会作者反思：评估用于重复细胞减灭术-热灌注化疗的热灌注化疗转换装置，是时候终止一种常见做法了吗？
Ann Surg Oncol. 2023 Jan;30(1):392-393. doi: 10.1245/s10434-022-12483-3. Epub 2022 Sep 6.
7
ASO Author Reflections: Palliative Management of Peritoneal Metastasis Exploring the Risks and Benefits of CRS/HIPEC, a Distinctly Different Context Than Early CRS/HIPEC Intervention With 'Curative Intent'.ASO作者反思：腹膜转移的姑息治疗——探索CRS/HIPEC的风险与益处，这与具有“治愈意图”的早期CRS/HIPEC干预背景截然不同。
Ann Surg Oncol. 2022 May;29(5):3347-3348. doi: 10.1245/s10434-022-11377-8. Epub 2022 Feb 25.
8
ASO Author Reflections: Reflections on the Impact of Access to CRS/HIPEC via Medicaid Expansion as a Key to Future Models for Advanced Surgical Cancer Care.美国外科医师学会作者反思：关于通过医疗补助扩大计划获得细胞减灭术/腹腔热灌注化疗对晚期外科癌症护理未来模式的影响的反思。
Ann Surg Oncol. 2025 Apr;32(4):2940-2941. doi: 10.1245/s10434-024-16556-3. Epub 2025 Jan 5.
9
ASO Author Reflections: PCI is Not Predictive of Survival After Complete CRS/HIPEC for High-Grade Appendiceal Primaries.ASO作者反思：对于高级别阑尾原发性肿瘤，PCI不能预测CRS/HIPEC完全切除术后的生存率。
Ann Surg Oncol. 2018 Dec;25(Suppl 3):769. doi: 10.1245/s10434-018-7027-z. Epub 2018 Nov 12.
10
ASO Author Reflections: Economics of Experience-Institutional Learning Curve of CRS-HIPEC.ASO作者反思：CRS-HIPEC的经验经济学——机构学习曲线
Ann Surg Oncol. 2024 Dec;31(13):8602-8603. doi: 10.1245/s10434-024-16093-z. Epub 2024 Sep 25.

本文引用的文献

1
EGFR Mutation Rates Correlate with Age at Diagnosis and Tumor Characteristics in Patients with Pulmonary Ground-Glass Opacities.肺磨玻璃影患者的表皮生长因子受体（EGFR）突变率与诊断时的年龄及肿瘤特征相关。
Ann Surg Oncol. 2024 Dec 25. doi: 10.1245/s10434-024-16730-7.
2
Prognostic Factors of Long-Term Survival and Conditional Survival Analysis in MPM Patients Treated with CRS+HIPEC: A Retrospective Study of Two Centers.接受CRS+HIPEC治疗的MPM患者长期生存的预后因素及条件生存分析：一项对两个中心的回顾性研究
Ann Surg Oncol. 2025 Apr;32(4):2912-2922. doi: 10.1245/s10434-024-16485-1. Epub 2024 Nov 13.
3
Conditional Survival Following Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Surface Malignancies: An Analysis from the US HIPEC Collaborative.
腹腔热灌注化疗联合细胞减灭术治疗腹膜表面恶性肿瘤的条件性生存：来自美国 HIPEC 协作组的分析。
Ann Surg Oncol. 2023 Mar;30(3):1840-1849. doi: 10.1245/s10434-022-12753-0. Epub 2022 Oct 30.
4
Nomogram of conditional survival probability of long-term Survival for Metastatic Colorectal Cancer: A Real-World Data Retrospective Cohort Study from SEER database.转移性结直肠癌长期生存条件生存概率列线图：来自 SEER 数据库的真实世界数据回顾性队列研究。
Int J Surg. 2021 Aug;92:106013. doi: 10.1016/j.ijsu.2021.106013. Epub 2021 Jul 4.
5
Treatment factors associated with long-term survival after cytoreductive surgery and regional chemotherapy for patients with malignant peritoneal mesothelioma.根治性手术和区域化疗治疗恶性腹膜间皮瘤患者的长期生存相关因素。
Surgery. 2013 Jun;153(6):779-86. doi: 10.1016/j.surg.2013.01.001. Epub 2013 Mar 13.
6
Current concepts in the evaluation and treatment of patients with diffuse malignant peritoneal mesothelioma.弥漫性恶性腹膜间皮瘤患者评估和治疗的当前概念。
J Natl Compr Canc Netw. 2012 Jan;10(1):49-57. doi: 10.6004/jnccn.2012.0008.